Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 54

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 54
---
2025, Compared to The Three Months Ended June 30, 2024

Total
Revenues. Revenues were $297,500 and $123,751 for the three months ended June 30, 2025 and 2024, respectively. Revenues in the
three months ended June 30, 2025, consist of sales of our Spryng® products of $148,243 and Precise PRP products of $149,257.
Revenues in the three months ended June 30, 2024, consisted of sales entirely of our Spryng® products of $123,751. The
increase in our revenues in the three months ended June 30, 2025, compared to the three months ended June 30, 2024, is due to sales of
Precise PRP products, pursuant to our exclusive licensing agreement with VetStem.

Cost
of Sales. Cost of sales were $110,774 and $12,994 for the three months ended June 30, 2025 and 2024, respectively. Cost of sales
includes product costs related to the sale of our Spryng® products, labor and overhead costs and product costs related
to the sale of Precise PRP products. The increase in our cost of sales in the three months ended June 30, 2025, compared to the three
months ended June 30, 2024, is due to sales of Precise PRP products.

Operating
Expenses. Operating expenses were $2,031,043 and $2,155,189 for the three months ended June 30, 2025 and 2024, respectively.
The decrease is primarily due to decreased general and administrative (“G&A”) expenses and research and development (“R&D”)
expenses.

27

General
and administrative (“G&A”) expenses were $1,068,818 and $1,233,261 for the three months ended June 30, 2025 and 2024,
respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting fees,
and stock compensation expenses.

Sales
and marketing expenses were $621,712 and $534,413 for the three months ended June 30, 2025 and 2024, respectively. Sales and marketing
expenses include compensation, consulting, tradeshows, and stock compensation costs to support the launch of our Spryng®
product.

Research
and development (“R&D”) expenses